Pancreatic Pill Doubles One-Year Survival in Trial
By @sharedot · · 7 pages
- Health
- Pancreatic Cancer
- Cancer Research
- Oncology
New trial data show 76.6% of advanced pancreatic cancer patients on daraxonrasib were alive at one year, roughly double the chemotherapy-alone rate.
Survival Numbers Are the New Development
The clearest new finding from the daraxonrasib trial is survival: one year after starting treatment, 76.6% of patients were still alive. Patients given chemotherapy alone historically survive a year at a rate of just 40-45%, meaning the daily pill roughly doubled one-year survival in this group.
Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who presented the findings at the EORTC-NCI-AACR Symposium in Barcelona, called the results 'the closest to cure' and said he had never seen so many tumours disappear in patients whose cancer had spread.
The Guardian and BBC both report the figures from the symposium.
What the Pill Does
Cancer Research UK's Dr Sam Godfrey told BBC News the drug had 'found a way of drugging the undruggable.' The trial combined the daily pill with chemotherapy (gemcitabine and nabpaclitaxel).
BBC reports the drug has already been approved in the US on an expedited basis, and that dozens of other cancers, including lung and ovarian, can carry similar mutations, raising hopes the approach could extend beyond pancreatic cancer.
Why This Matters
Pancreatic cancer remains one of medicine's deadliest challenges. Half of all people diagnosed die within three months, and only about 3% of patients survive five years once the disease spreads to other organs, according to The Guardian.
For patients with advanced disease, options have been scarce for decades.
Caution From Doctors
Doctors stress the pill is not yet a cure, and it is unclear how long it can keep the disease at bay.
In the phase I/II trial of 61 patients with recently diagnosed advanced pancreatic cancer that had spread, tumours stopped growing in 90%, just over 60% saw tumours shrink or disappear, and in about 8% — one in 12 — tumours became undetectable on CT scans.
Michelle Mitchell, Cancer Research UK's chief executive, said more research is needed but called the results 'the biggest leap forward we've seen in decades.'
Prof Elena Garralda, chair of the Barcelona symposium, said the findings suggest the combined treatment could improve overall survival and time before tumours regrow.
What Comes Next
Patients were followed for about 18 months on average, and some saw no cancer return during that period; Park described the possibility of disease simply disappearing on CT scans within that window as 'incredible.'
Longer studies are planned to test whether any of these cancers can be put into durable remission. Cancer Research UK notes more trials are needed before the treatment can be assessed for use on the NHS, and that pancreatic cancer survival remains very low despite the advance.
Godfrey told BBC that cancer can come back even when scans show no sign of it, so more time must pass before patients can be considered cancer-free.